Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis |
| |
Authors: | Yasar Levent Sönmez Ali Süha Utku Nurhan Ozcan Jane Cebi Ziya Savan Kadir Sut Necdet Yazicioğlu Fehmi |
| |
Institution: | 1. Department of Cardiology, Swiss Cardiovascular Center, University Hospital, Bern;2. Department of Cardiology, University Hospital, Geneva;3. Department of Cardiology, Triemlispital, Zurich;4. Department of Cardiology, University Hospital, Lausanne;5. Department of Cardiology, Kantonsspital, Aarau;6. Department of Cardiology, University Hospital, Fribourg;7. Department of Cardiology, Kantonsspital, St Gallen;8. Department of Cardiology, University Hospital, Basel;9. Department of Cardiology, Kantonsspital, Luzern, Switzerland;10. Institute of Social and Preventive Medicine and Clinical Trials Unit, Bern University Hospital, Bern, Switzerland |
| |
Abstract: | OBJECTIVE: To evaluate the effect of misoprostol on bone mineral density in postmenopausal women. MATERIALS AND METHODS: The study was performed in a randomized controlled prospective manner in 90 women with menopause at Süleymaniye Maternity and Women's Diseases Teaching and Research Hospital between January and December 2003. Cases were divided into three groups each consisting of 30 women who were in menopause for at least 1 year and had t-scores less than -1 by dual energy X-ray densitometry (DEXA). Group I was treated with misoprostol and calcium, Group II received tibolone and calcium and Group III was given calcium only and considered as control group. In all patients, bone mineral density in L1-L4 vertebrae, femur neck and Ward triangle were measured by DEXA and t and z scores were calculated. RESULTS: All groups were similar demographically. Bone mineral density in L1-L4 vertebrae, femur neck and Ward triangle in the group treated with misoprostol, increased by 5, 8.1 and 3.6%, respectively. In the tibolone group, bone mineral density in L1-L4 vertebrae, femur neck and Ward triangle increased by 8.3, 5.3 and 7.8%, respectively. There was not a significant difference in t and z-scores and bone mineral density measurements between misoprostol and tibolon groups. CONCLUSION: Misoprostol may be an alternative treatment for patients with osteopenia and osteoporosis who are not suitable for hormone replacement therapy. |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|